[{"orgOrder":0,"company":"Laboratorios Roemmers","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ARGENTINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"Laboratorios Roemmers","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Laboratorios Roemmers \/ Inapplicable","highestDevelopmentStatusID":"9","companyTruncated":"Laboratorios Roemmers \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"INDIA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"ANI Pharmaceuticals Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Gastroenterology","graph2":"Approved FDF","graph3":"ANI Pharmaceuticals Inc","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral Tablet, Film Coated","sponsorNew":"ANI Pharmaceuticals Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ANI Pharmaceuticals Inc \/ Inapplicable"},{"orgOrder":0,"company":"Materno-Perinatal Hospital of the State of Mexico","sponsor":"Liomont","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Materno-Perinatal Hospital of the State of Mexico","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Materno-Perinatal Hospital of the State of Mexico \/ Liomont","highestDevelopmentStatusID":"11","companyTruncated":"Materno-Perinatal Hospital of the State of Mexico \/ Liomont"},{"orgOrder":0,"company":"Azidus Brazil","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus Brazil","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Azidus Brazil \/ Farmoquimica","highestDevelopmentStatusID":"10","companyTruncated":"Azidus Brazil \/ Farmoquimica"},{"orgOrder":0,"company":"Romark","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Romark \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Inapplicable"},{"orgOrder":0,"company":"Azidus Brazil","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus Brazil","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Azidus Brazil \/ Farmoquimica","highestDevelopmentStatusID":"10","companyTruncated":"Azidus Brazil \/ Farmoquimica"},{"orgOrder":0,"company":"Romark","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Romark \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Inapplicable"},{"orgOrder":0,"company":"Romark","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Romark \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Inapplicable"},{"orgOrder":0,"company":"Romark","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Romark \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Inapplicable"},{"orgOrder":0,"company":"Romark","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Romark \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Inapplicable"},{"orgOrder":0,"company":"Romark","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Romark \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Inapplicable"},{"orgOrder":0,"company":"Romark","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Romark \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Inapplicable"},{"orgOrder":0,"company":"Romark","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Romark \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Inapplicable"},{"orgOrder":0,"company":"Romark","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Romark","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Romark \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Romark \/ Inapplicable"},{"orgOrder":0,"company":"NovaLead Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"NovaLead Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"NovaLead Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"NovaLead Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Azidus Brazil","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus Brazil","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Azidus Brazil \/ Farmoquimica","highestDevelopmentStatusID":"10","companyTruncated":"Azidus Brazil \/ Farmoquimica"},{"orgOrder":0,"company":"Azidus Brazil","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus Brazil","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Azidus Brazil \/ Farmoquimica","highestDevelopmentStatusID":"10","companyTruncated":"Azidus Brazil \/ Farmoquimica"},{"orgOrder":0,"company":"Azidus Brazil","sponsor":"Farmoquimica | Hospital Vera Cruz | Hospital Casa de Sa\u00fade - Vera Cruz - Campinas - SP - Brazil | Centro de Genomas UNIFESP | Fuzhou Pulmonary Hospital of Fujian","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Azidus Brazil","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Azidus Brazil \/ Farmoquimica | Hospital Vera Cruz | Hospital Casa de Sa\u00fade - Vera Cruz - Campinas - SP - Brazil | Centro de Genomas UNIFESP | Fuzhou Pulmonary Hospital of Fujian","highestDevelopmentStatusID":"10","companyTruncated":"Azidus Brazil \/ Farmoquimica | Hospital Vera Cruz | Hospital Casa de Sa\u00fade - Vera Cruz - Campinas - SP - Brazil | Centro de Genomas UNIFESP | Fuzhou Pulmonary Hospital of Fujian"},{"orgOrder":0,"company":"Fundaci\u00f3n Hu\u00e9sped","sponsor":"Ministry of Health, Buenos Aires | Laboratorios Roemmers","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Fundaci\u00f3n Hu\u00e9sped","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundaci\u00f3n Hu\u00e9sped \/ Ministry of Health, Buenos Aires | Laboratorios Roemmers","highestDevelopmentStatusID":"11","companyTruncated":"Fundaci\u00f3n Hu\u00e9sped \/ Ministry of Health, Buenos Aires | Laboratorios Roemmers"},{"orgOrder":0,"company":"Rutgers, The State University of New Jersey","sponsor":"SynaVir","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II","graph3":"Rutgers, The State University of New Jersey","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rutgers, The State University of New Jersey \/ SynaVir","highestDevelopmentStatusID":"8","companyTruncated":"Rutgers, The State University of New Jersey \/ SynaVir"},{"orgOrder":0,"company":"Genfit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase II","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genfit \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Genfit \/ Inapplicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"FRANCE","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase I","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hepatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genfit \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genfit \/ Inapplicable"},{"orgOrder":0,"company":"Genfit","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"FRANCE","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Nitazoxanide","moa":"Pyruvate:ferredoxin oxidoreductase","graph1":"Nephrology","graph2":"Phase I","graph3":"Genfit","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genfit \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genfit \/ Inapplicable"}]
Find Clinical Drug Pipeline Developments & Deals for Nitazoxanide
Details :
Alinia-Generic (nitazoxanide) is an antiprotozoal indicated for the treatment of diarrhea caused by giardia lamblia or cryptosporidium parvum.
Details :
GENFIT is launching a clinical program with nitazoxanide (NTZ) in this disease. A Phase 1 study to evaluate pharmacokinetics and pharmacodynamics in patients with varying degrees of hepatic impairment is expected to start in 4Q21 with clinical data expec...
Details :
Nitazoxanide Tablets, 500 mg, are indicated in the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 years of age and older.
Details :
NT-300 is an oral, broad-spectrum antiviral drug designed to provide antiviral concentrations of drug to the respiratory tract throughout twice-daily dosing.
Reset All
